Cargando…

Evaluation of Serum Lipid, Thyroid, and Hepatic Clinical Chemistries in Association With Serum Perfluorooctanesulfonate (PFOS) in Cynomolgus Monkeys After Oral Dosing With Potassium PFOS

An oral dose study with perfluorooctanesulfonate (PFOS) was undertaken to identify potential associations between serum PFOS and changes in serum clinical chemistry parameters in purpose-bred young adult cynomolgus monkeys (Macaca fascicularis). In this study, control group (n = 6/sex) was sham-dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Sue, Allen, Bruce C., Andres, Kara L., Ehresman, David J., Falvo, Ria, Provencher, Anne, Olsen, Geary W., Butenhoff, John L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412069/
https://www.ncbi.nlm.nih.gov/pubmed/28115654
http://dx.doi.org/10.1093/toxsci/kfw267
_version_ 1783232915021234176
author Chang, Sue
Allen, Bruce C.
Andres, Kara L.
Ehresman, David J.
Falvo, Ria
Provencher, Anne
Olsen, Geary W.
Butenhoff, John L.
author_facet Chang, Sue
Allen, Bruce C.
Andres, Kara L.
Ehresman, David J.
Falvo, Ria
Provencher, Anne
Olsen, Geary W.
Butenhoff, John L.
author_sort Chang, Sue
collection PubMed
description An oral dose study with perfluorooctanesulfonate (PFOS) was undertaken to identify potential associations between serum PFOS and changes in serum clinical chemistry parameters in purpose-bred young adult cynomolgus monkeys (Macaca fascicularis). In this study, control group (n = 6/sex) was sham-dosed with vehicle (0.5% Tween 20 and 5% ethanol in water), low-dose group (n = 6/sex) received 1 single K(+)PFOS dose (9 mg/kg), and high-dose group (n = 4–6/sex) received 3 separate K(+) PFOS doses (11–17.2 mg/kg). Monkeys were given routine checkups and observed carefully for health problems on a daily basis. Scheduled blood samples were drawn from all monkeys prior to, during, and after K(+)PFOS administration for up to 1 year and they were analyzed for PFOS concentrations and clinical chemistry markers for coagulation, lipids, hepatic, renal, electrolytes, and thyroid-related hormones. No mortality occurred during the study. All the monkeys were healthy, gained weight, and were released back to the colony at the end of the study. The highest serum PFOS achieved was approximately 165 μg/ml. When compared with time-matched controls, administration of K(+)PFOS to monkeys did not result in any toxicologically meaningful or clinically relevant changes in serum clinical measurements for coagulation, lipids, hepatic, renal, electrolytes, and thyroid-related hormones. A slight reduction in serum cholesterol (primarily the high-density lipoprotein fraction), although not toxicologically significant, was observed. The corresponding lower-bound fifth percentile benchmark concentrations (BMCL(1sd)) were 74 and 76 μg/ml for male and female monkeys, respectively. Compared to the 2013–2014 geometric mean serum PFOS level of 4.99 ng/ml (0.00499 μg/ml) in US general population reported by CDC NHANES, this represents 4 orders of magnitude for margin of exposure.
format Online
Article
Text
id pubmed-5412069
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-54120692017-05-05 Evaluation of Serum Lipid, Thyroid, and Hepatic Clinical Chemistries in Association With Serum Perfluorooctanesulfonate (PFOS) in Cynomolgus Monkeys After Oral Dosing With Potassium PFOS Chang, Sue Allen, Bruce C. Andres, Kara L. Ehresman, David J. Falvo, Ria Provencher, Anne Olsen, Geary W. Butenhoff, John L. Toxicol Sci PFOS Effects in Monkeys An oral dose study with perfluorooctanesulfonate (PFOS) was undertaken to identify potential associations between serum PFOS and changes in serum clinical chemistry parameters in purpose-bred young adult cynomolgus monkeys (Macaca fascicularis). In this study, control group (n = 6/sex) was sham-dosed with vehicle (0.5% Tween 20 and 5% ethanol in water), low-dose group (n = 6/sex) received 1 single K(+)PFOS dose (9 mg/kg), and high-dose group (n = 4–6/sex) received 3 separate K(+) PFOS doses (11–17.2 mg/kg). Monkeys were given routine checkups and observed carefully for health problems on a daily basis. Scheduled blood samples were drawn from all monkeys prior to, during, and after K(+)PFOS administration for up to 1 year and they were analyzed for PFOS concentrations and clinical chemistry markers for coagulation, lipids, hepatic, renal, electrolytes, and thyroid-related hormones. No mortality occurred during the study. All the monkeys were healthy, gained weight, and were released back to the colony at the end of the study. The highest serum PFOS achieved was approximately 165 μg/ml. When compared with time-matched controls, administration of K(+)PFOS to monkeys did not result in any toxicologically meaningful or clinically relevant changes in serum clinical measurements for coagulation, lipids, hepatic, renal, electrolytes, and thyroid-related hormones. A slight reduction in serum cholesterol (primarily the high-density lipoprotein fraction), although not toxicologically significant, was observed. The corresponding lower-bound fifth percentile benchmark concentrations (BMCL(1sd)) were 74 and 76 μg/ml for male and female monkeys, respectively. Compared to the 2013–2014 geometric mean serum PFOS level of 4.99 ng/ml (0.00499 μg/ml) in US general population reported by CDC NHANES, this represents 4 orders of magnitude for margin of exposure. Oxford University Press 2017-04 2017-01-23 /pmc/articles/PMC5412069/ /pubmed/28115654 http://dx.doi.org/10.1093/toxsci/kfw267 Text en © The Author 2017. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle PFOS Effects in Monkeys
Chang, Sue
Allen, Bruce C.
Andres, Kara L.
Ehresman, David J.
Falvo, Ria
Provencher, Anne
Olsen, Geary W.
Butenhoff, John L.
Evaluation of Serum Lipid, Thyroid, and Hepatic Clinical Chemistries in Association With Serum Perfluorooctanesulfonate (PFOS) in Cynomolgus Monkeys After Oral Dosing With Potassium PFOS
title Evaluation of Serum Lipid, Thyroid, and Hepatic Clinical Chemistries in Association With Serum Perfluorooctanesulfonate (PFOS) in Cynomolgus Monkeys After Oral Dosing With Potassium PFOS
title_full Evaluation of Serum Lipid, Thyroid, and Hepatic Clinical Chemistries in Association With Serum Perfluorooctanesulfonate (PFOS) in Cynomolgus Monkeys After Oral Dosing With Potassium PFOS
title_fullStr Evaluation of Serum Lipid, Thyroid, and Hepatic Clinical Chemistries in Association With Serum Perfluorooctanesulfonate (PFOS) in Cynomolgus Monkeys After Oral Dosing With Potassium PFOS
title_full_unstemmed Evaluation of Serum Lipid, Thyroid, and Hepatic Clinical Chemistries in Association With Serum Perfluorooctanesulfonate (PFOS) in Cynomolgus Monkeys After Oral Dosing With Potassium PFOS
title_short Evaluation of Serum Lipid, Thyroid, and Hepatic Clinical Chemistries in Association With Serum Perfluorooctanesulfonate (PFOS) in Cynomolgus Monkeys After Oral Dosing With Potassium PFOS
title_sort evaluation of serum lipid, thyroid, and hepatic clinical chemistries in association with serum perfluorooctanesulfonate (pfos) in cynomolgus monkeys after oral dosing with potassium pfos
topic PFOS Effects in Monkeys
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412069/
https://www.ncbi.nlm.nih.gov/pubmed/28115654
http://dx.doi.org/10.1093/toxsci/kfw267
work_keys_str_mv AT changsue evaluationofserumlipidthyroidandhepaticclinicalchemistriesinassociationwithserumperfluorooctanesulfonatepfosincynomolgusmonkeysafteroraldosingwithpotassiumpfos
AT allenbrucec evaluationofserumlipidthyroidandhepaticclinicalchemistriesinassociationwithserumperfluorooctanesulfonatepfosincynomolgusmonkeysafteroraldosingwithpotassiumpfos
AT andreskaral evaluationofserumlipidthyroidandhepaticclinicalchemistriesinassociationwithserumperfluorooctanesulfonatepfosincynomolgusmonkeysafteroraldosingwithpotassiumpfos
AT ehresmandavidj evaluationofserumlipidthyroidandhepaticclinicalchemistriesinassociationwithserumperfluorooctanesulfonatepfosincynomolgusmonkeysafteroraldosingwithpotassiumpfos
AT falvoria evaluationofserumlipidthyroidandhepaticclinicalchemistriesinassociationwithserumperfluorooctanesulfonatepfosincynomolgusmonkeysafteroraldosingwithpotassiumpfos
AT provencheranne evaluationofserumlipidthyroidandhepaticclinicalchemistriesinassociationwithserumperfluorooctanesulfonatepfosincynomolgusmonkeysafteroraldosingwithpotassiumpfos
AT olsengearyw evaluationofserumlipidthyroidandhepaticclinicalchemistriesinassociationwithserumperfluorooctanesulfonatepfosincynomolgusmonkeysafteroraldosingwithpotassiumpfos
AT butenhoffjohnl evaluationofserumlipidthyroidandhepaticclinicalchemistriesinassociationwithserumperfluorooctanesulfonatepfosincynomolgusmonkeysafteroraldosingwithpotassiumpfos